Amgen and CytomX Therapeutics announce strategic collaboration in immuno-oncology
Amgen and CytomX Therapeutics, Inc, today announced that the companies have entered into a strategic collaboration in immuno-oncology. The companies will co-develop a CytomX ProbodyTM T-cell engaging bispecific against the Epidermal Growth Factor Receptor (EGFR), a highly validated oncology target expressed on multiple human cancer types.